Why Is Tenax Therapeutics (TENX) Stock Down -88.10% Today?
Key Takeaways
- Tenax Therapeutics shares plummeted approximately 88% to $1.60 after the company announced its Phase 3 LEVEL trial of TNX-103 failed to meet its primary endpoint.
- The trial missed both the primary endpoint — improvement in six-minute walk distance — and the key secondary endpoint measuring symptom improvement via the Kansas City Cardiomyopathy Questionnaire.
- The failure represents a devastating binary event for the pre-revenue biotech, which had drawn significant bullish analyst coverage and investor positioning ahead of the readout.
- Several Wall Street firms had recently initiated coverage or raised price targets — some as high as $50 — betting on a positive outcome for the drug in an indication with no approved therapies.
- Broader markets showed modest gains, confirming the collapse in TENX was entirely company-specific and disconnected from macroeconomic headwinds.
- Attention now shifts to the ongoing global Phase 3 LEVEL-2 trial and whether the company's $118 million cash runway can support a revised regulatory strategy.
Opening Summary
TENX, the clinical-stage biotechnology company focused on cardiovascular and pulmonary diseases with high unmet medical needs, saw its stock crater roughly 88% in Monday's trading session after topline results from the highly anticipated Phase 3 LEVEL trial showed the company's lead drug candidate, TNX-103, failed to demonstrate statistically significant benefits over placebo. The stock, which closed at $13.44 on Friday, August 7, 2026, traded near $1.60 on Monday, wiping out hundreds of millions in market capitalization in one of the most severe single-day biotech selloffs of the year.
Phase 3 LEVEL Trial Misses Primary and Secondary Endpoints
The catastrophic move was triggered by Tenax's disclosure that the Phase 3 LEVEL study evaluating TNX-103 — an oral formulation of levosimendan — in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not achieve its primary endpoint. The trial, which enrolled 241 patients across 41 sites in North America, showed a least-squares mean difference of just 3.5 meters in six-minute walk distance compared with placebo, with a p-value of 0.63 — far from statistical significance.
Compounding the disappointment, the study also failed to reach its key secondary endpoint measuring improvement in the Kansas City Cardiomyopathy Questionnaire total symptom score. The double miss represents a near-total wipeout of the investment thesis that had driven the stock higher in the weeks leading up to the data readout.
Wall Street Optimism Collapses
The scale of Monday's selloff reflects the depth of bullish positioning that had accumulated around TENX ahead of the trial results. In recent weeks, multiple prominent firms — including Chardan, Guggenheim, Piper Sandler, Canaccord, and Evercore ISI — had initiated coverage or raised price targets on the stock, with some objectives reaching as high as $50 per share. Analysts had touted TNX-103's potential in an indication that currently has no FDA-approved therapies, creating a powerful narrative that attracted substantial investor interest.
Adding to the sense of dashed expectations, Tenax had recently hired a Chief Commercial Officer specifically to prepare for a potential product launch — a move that signaled management's own confidence in a favorable outcome and now appears premature in hindsight. On the positive side, the company did note that prespecified subgroup analyses identified a beneficial treatment effect in patients with a greater disease burden, and TNX-103 was reported to be generally safe and well tolerated, with balanced serious adverse events between treatment and placebo arms.
Market Context and Trading Activity
The plunge in TENX stands in stark contrast to the broader market, where S&P 500 and NASDAQ futures pointed modestly higher, supported by last Friday's weaker-than-expected July employment data that reduced near-term rate-hike concerns. This confirms the move is entirely company-specific and not attributable to any adverse macroeconomic or sector-wide pressures. Trading volume was extraordinarily elevated, reflecting panicked liquidation by investors who had positioned for a positive binary outcome. The stock's collapse likely triggered significant margin calls and stop-loss cascades that amplified the intraday selling pressure.
What Comes Next for TENX
With the LEVEL trial now recorded as a failure, investor focus pivots entirely to the path forward. Tenax management said it intends to request a Type C meeting with the FDA to discuss potential modifications to the ongoing registrational development program for TNX-103 in PH-HFpEF, leaning on the subgroup efficacy signals and favorable safety profile as justification for continued development. The company's cash position of approximately $118 million, which management previously estimated would fund operations into mid-2028, provides a financial buffer — but also raises questions about whether capital will be redirected toward the ongoing global Phase 3 LEVEL-2 trial or toward entirely new strategic priorities. For a pre-revenue biotech with no fallback pipeline assets of comparable significance, the stakes could not be higher. Risks include potential shareholder litigation, loss of key talent, and the possibility that the FDA signals an unwillingness to accept subgroup analyses as a basis for approval.
Trending AI Robots
For traders seeking to navigate volatile biotech and small-cap markets with data-driven strategies, Tickeron offers a curated selection of Trending AI Robots. With hundreds of AI-powered trading bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics, Tickeron highlights only the strongest performers under current market conditions in this dedicated section. Each robot is designed to identify patterns and execute trades based on technical and fundamental signals, offering a systematic approach to markets where emotional decision-making often leads to losses. Explore the Trending AI Robots to see which automated strategies are currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TENX's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for TENX moved out of overbought territory on July 13, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TENX turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .
TENX moved below its 50-day moving average on August 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TENX entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TENX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.429) is normal, around the industry mean (20.179). P/E Ratio (2.415) is within average values for comparable stocks, (26.004). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.625). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (463.689).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapeutic products
Industry Biotechnology